Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity

PURPOSE: SABR has demonstrated clinical benefit in oligometastatic prostate cancer. However, the risk of developing new distant metastatic lesions remains high, and only a minority of patients experience durable progression-free response. Therefore, there is a critical need to identify which patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucien, Fabrice, Kim, Yohan, Qian, Jing, Orme, Jacob J., Zhang, Henan, Arafa, Ali, Abraha, Feven, Thapa, Ishwor, Tryggestad, Erik J., Harmsen, William S., Kosti, Jorgena, Ali, Hesham, Lowe, Val J., Johnson, Geoff B., Kwon, Eugene D., Dong, Haidong, Park, Sean S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869345/
https://www.ncbi.nlm.nih.gov/pubmed/35671867
http://dx.doi.org/10.1016/j.ijrobp.2022.05.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869345/
https://www.ncbi.nlm.nih.gov/pubmed/35671867
http://dx.doi.org/10.1016/j.ijrobp.2022.05.037

Ejemplares similares